Is Arcadia Biosciences, Inc. overvalued or undervalued?

As of 30 March 2022, the valuation grade for Arcadia Biosciences, Inc. has moved from attractive to risky, indicating a significant deterioration in its financial standing. The company is currently deemed overvalued, with a P/E ratio of 7, which is notably lower than its peers such as CVR Partners LP at 12.50 and Oil-Dri Corp. of America at 22.31. Additionally, Arcadia's Price to Book Value stands at 0.76, while its EV to EBITDA is at a troubling -0.76, reflecting negative operational performance.
In comparison to its peers, Arcadia's PEG ratio of 0.07 further underscores its valuation challenges, especially when juxtaposed with the industry averages. The company's ROCE is alarmingly low at -91.54%, and despite a recent one-year stock return of 38.74%, it has underperformed significantly against the S&P 500 over longer periods. This combination of poor financial ratios and relative performance suggests that Arcadia Biosciences, Inc. is currently overvalued in the market.